Cargando…

Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?

BACKGROUND AND OBJECTIVE: Patients with focal seizures recruited into adjunctive antiepileptic drug (AED) trials have become more refractory and severe over time; concurrently, placebo responses have increased. To attempt to account for heterogeneity among trials, propensity-score weighted patient-l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swallow, Elyse, Fang, Anna, Signorovitch, James, Plumb, Jonathan, Borghs, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658476/ https://www.ncbi.nlm.nih.gov/pubmed/28856580 http://dx.doi.org/10.1007/s40263-017-0462-8

Ejemplares similares

Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison
por: Signorovitch, James, et al.
Publicado: (2013)

Overnight switch from levetiracetam to brivaracetam. Safety and tolerability
por: Abraira, L., et al.
Publicado: (2021)

Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam
por: Mukuria, Clara, et al.
Publicado: (2016)

Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience
por: Steinhoff, Bernhard J., et al.
Publicado: (2019)

The Integrated Effects of Brivaracetam, a Selective Analog of Levetiracetam, on Ionic Currents and Neuronal Excitability
por: Hung, Te-Yu, et al.
Publicado: (2021)

Time course of 75%–100% efficacy response of adjunctive brivaracetam
por: Klein, Pavel, et al.
Publicado: (2020)

Clinical and Economic Outcomes of Intravenous Brivaracetam Compared With Levetiracetam for the Treatment of Seizures in United States Hospitals
por: Beaty, Silky, et al.
Publicado: (2021)

Long‐term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11‐year, open‐label, follow‐up trial
por: O’Brien, Terence J., et al.
Publicado: (2020)

Adjunctive Brivaracetam in Older Patients with Focal Seizures: Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST)
por: Lattanzi, Simona, et al.
Publicado: (2022)

Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)
por: Lattanzi, Simona, et al.
Publicado: (2021)

Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures
por: Lattanzi, Simona, et al.
Publicado: (2022)

Correction to: Adjunctive Brivaracetam in Focal Epilepsy: Real‑World Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST)
por: Lattanzi, Simona, et al.
Publicado: (2021)

Brivaracetam and Levetiracetam Suppress Astroglial L-Glutamate Release through Hemichannel via Inhibition of Synaptic Vesicle Protein
por: Fukuyama, Kouji, et al.
Publicado: (2022)

Economic Value of Adjunctive Brivaracetam Treatment Strategy for Focal Onset Seizures in Finland
por: Väätäinen, Saku, et al.
Publicado: (2019)

Neuropsychological implications of adjunctive levetiracetam in childhood epilepsy
por: Posar, Annio, et al.
Publicado: (2014)

Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures
por: Mumoli, Laura, et al.
Publicado: (2015)

Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients < 16 Years with Epilepsy: An Open-Label Trial
por: Liu, Edwin, et al.
Publicado: (2019)

Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy Patients
por: Reed, Ronald C., et al.
Publicado: (2020)

Two-stage matching-adjusted indirect comparison
por: Remiro-Azócar, Antonio
Publicado: (2022)

Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures [Corrigendum]
Publicado: (2015)

Assessment of the biomarkers of hepatotoxicity following carbamazepine, levetiracetam, and carbamazepine-levetiracetam adjunctive treatment in male Wistar rats
por: Osuntokun, Opeyemi Samson, et al.
Publicado: (2021)

Acute and long‐term effects of brivaracetam and brivaracetam–diazepam combinations in an experimental model of status epilepticus
por: Niquet, Jerome, et al.
Publicado: (2017)

Are doses of lamotrigine or levetiracetam adjusted during pregnancy?
por: Richards, Noni, et al.
Publicado: (2017)

Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy
por: de MANREZA, Maria Luiza Giraldes, et al.
Publicado: (2021)

Correction: Two-stage matching-adjusted indirect comparison
por: Remiro‑Azócar, Antonio
Publicado: (2022)

A single‐center, open‐label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers
por: Finnema, Sjoerd J., et al.
Publicado: (2019)

Drug characteristics derived from kinetic modeling: combined (11)C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A
por: Naganawa, Mika, et al.
Publicado: (2022)

Adjunctive levetiracetam in the treatment of Chinese and Japanese adults with generalized tonic–clonic seizures: A double‐blind, randomized, placebo‐controlled trial
por: Wu, Liwen, et al.
Publicado: (2018)

Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching‐adjusted indirect comparison
por: Bewley, A.P., et al.
Publicado: (2019)

Profile of brivaracetam and its potential in the treatment of epilepsy
por: Ferlazzo, Edoardo, et al.
Publicado: (2015)

A review of the pharmacology and clinical efficacy of brivaracetam
por: Klein, Pavel, et al.
Publicado: (2018)

Comparative Efficacy of Guanfacine Extended Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Applying Matching-Adjusted Indirect Comparison Methodology
por: Sikirica, Vanja, et al.
Publicado: (2013)

Lacosamide and sodium channel‐blocking antiepileptic drug cross‐titration against levetiracetam background therapy
por: Baulac, M., et al.
Publicado: (2016)

Equivalence of entropy balancing and the method of moments for matching‐adjusted indirect comparison
por: Phillippo, David M., et al.
Publicado: (2020)

Levetiracetam mitigates doxorubicin-induced DNA and synaptic damage in neurons
por: Manchon, Jose Felix Moruno, et al.
Publicado: (2016)

Authors’ Reply to Alatorre et al.: “Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison”
por: Erder, M. Haim, et al.
Publicado: (2013)

Brivaracetam in the Treatment of Patients with Epilepsy—First Clinical Experiences
por: Zahnert, Felix, et al.
Publicado: (2018)

Synthetic Approaches toward the Synthesis of Brivaracetam: An Antiepileptic Drug
por: Gayke, Manoj, et al.
Publicado: (2022)

Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials
por: Ryvlin, Philippe, et al.
Publicado: (2022)

A Critical Appraisal of Matching-Adjusted Indirect Comparisons in Spinal Muscular Atrophy
por: Jiang, Tammy, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hl1ul88os8e7lqg9lfampd57ij